Get the Stockscreener App
2.48
5.08%
0.12
After Hours:
2.54
0.06
+2.42%
Organogenesis Holdings Inc stock is traded at $2.48, with a volume of 646.57K.
It is up +5.08% in the last 24 hours and up +2.48% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$2.36
Open:
$2.37
24h Volume:
646.57K
Relative Volume:
0.45
Market Cap:
$319.11M
Revenue:
$514.70M
Net Income/Loss:
$2.72M
P/E Ratio:
-15.61
EPS:
-0.1589
Net Cash Flow:
$17.08M
1W Performance:
+2.48%
1M Performance:
+2.48%
6M Performance:
-43.12%
1Y Performance:
-41.65%
1-Day Range:
$2.345
$2.485
1-Week Range:
$2.305
$2.485
52-Week Range:
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.48 | 312.68M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Enterprise value to revenue forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis | 10-K: FY2025 Annual Report - Moomoo
Enterprise value to EBITDA forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to earnings forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM: ORGO) added to Russell 2000 Value Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO) - TradingView
ORGO Forecast — Price Target — Prediction for 2027 - TradingView
Organogenesis Holdings Inc (ORGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis Holdings Inc (ORGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spotlight On 3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Organogenesis Holdings Inc (ORGO) Institutional Confidence - TradingKey
Organogenesis Holdings Inc (ORGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organogenesis Holdings Inc (ORGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organogenesis Holdings Inc - TradingKey
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Organogenesis Holdings Inc (ORGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Organogenesis re-elects Garrett Lustig to its board - TradingView
Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay - Stock Titan
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It - GlobeNewswire
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesEPS Guidance Update - newsline.com
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
Organogenesis Holdings (ORGO) Consolidates Near Support After Marginal DeclineVolatility Skew - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis Holdings (ORGO) Slides 1.65% as It Tests Key Support at $2.26KAMA Signal - Město Břeclav
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - Newswire Canada
Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ - TradingView
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings Faces Selling Pressure as ORGO Slips to $2.57Oversold Bounce Ideas - newsline.com
Organogenesis Holdings (ORGO) Declines 1.5% as Stock Tests Key Support ZoneFund Manager Survey - The Legal Advocate
Truist initiates Organogenesis stock at Hold on reimbursement shifts - Investing.com UK
Truist initiates Organogenesis stock at Hold on reimbursement shifts By Investing.com - Investing.com India
Truist Initiates Organogenesis Holdings at Hold With $3 Price Target - marketscreener.com
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
ORGOOrganogenesis Holdings Inc Stock Price and Quote - Finviz
- The Legal Advocate
Organogenesis Holdings (ORGO) Edges Lower as Stock Hovers Near Key SupportBullish Percent Index - The Legal Advocate
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings (ORGO) Holds Steady at $2.66 – Consolidation Phase in PlayALMA Signal - The Legal Advocate
ORGO Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational ChallengesEPS Miss Report - newsline.com
ORGO Q1 2026 Earnings: Significant EPS Miss Raises ConcernsSlow Growth Warning - newsline.com
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):